Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatmen

chapter 1|12 pages

BCR-ABL as a Molecular Target

ByMichael Deininger

chapter 2|14 pages

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia

ByMukta Arora, Mary M. Horowitz

chapter 3|18 pages

Where Are We Today with Imatinib Therapy?

ByJohn M. Goldman

chapter 4|14 pages

Monitoring Chronic Myeloid Leukemia in 2006

ByNicola Hurst, Timothy P. Hughes, Susan Branford

chapter 5|10 pages

Dasatinib: A Dual ABL and SRC Inhibitor

ByAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes

chapter 6|10 pages

Nilotinib (AMN107) for the Treatment of Chronic Myelogenous Leukemia

ByElias Jabbour, Francis Giles, Jorge Cortes, Susan O’Brien, Hagop Kantarjian

chapter 7|16 pages

Resistance to Imatinib

ByDuyster Justus, Bubnoff Nikolas von

chapter 8|14 pages

Immunotherapy of Chronic Myeloid Leukemia

ByBocchia Monica, Lauria Francesco

chapter 9|16 pages

Molecular Targets Other than BCR-ABL: How to Incorporate them into the CML Therapy?

ByV. Melo Junia, J. Barnes David

chapter 11|8 pages

Early Intensification of Therapy: The Role of High-Dose Imatinib and Imatinib-Based Combinations

ByGuilhot François, Martineau Géraldine, Millot Frédéric, Roy Lydia